Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2B | P41595 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699524 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL5894706 | 0.98 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Methyl Alcohol SCHEMBL28137463 | 0.95 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL27587863 | 0.90 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL1945934 | 0.90 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL28597180 | 0.89 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Propanol SCHEMBL27627306 | 0.88 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Cyclohexanone SCHEMBL27571035 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL7998290 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL28597186 | 0.85 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 526 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | TWINCORE ZENTRUM FUR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2022-01-27 | — | — | US | claimed |
| WO-2021262825-A2 | DISRUPTING LIPID SYNTHESIS: A NOVEL TARGET FOR BROAD-SPECTRUM HOST-DIRECTED ANTI-VIRULENCE THERAPEUTICS | GENETIC NETWORKS, LLC (US) | 2021-12-30 | — | — | WO | claimed |
| EP-3898593-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2021-10-27 | — | — | EP | claimed |
| WO-2020127211-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) | 2020-06-25 | — | — | WO | claimed |
| EP-3670498-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2020-06-24 | — | — | EP | claimed |
| CN-111138713-A | Stearylamine modified ammonium polyphosphate and preparation method and application thereof | 上海普利特复合材料股份有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-107556255-A | A kind of organic amine modified melamine polyphosphate and preparation method thereof | 东华大学 | 2018-01-09 | — | — | CN | claimed |
| CN-107459492-A | A kind of organically-modified melamine polyphosphate and preparation method thereof | 东华大学 | 2017-12-12 | — | — | CN | claimed |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | claimed |
| EP-1269990-B1 | Cosmetic or dermatological composition comprising acylaminoamide derivatives | OREAL (FR) | 2010-10-13 | — | — | EP | claimed |
| US-6344461-B1 | Treating skin wrinkles/fine lines with calcium channel inhibitors | SOCIETE L'OREAL S.A. (FR) | 2002-02-05 | — | — | US | claimed |
| EP-0549796-B1 | DIPHENYLPIPERAZINE DERIVATIVE AND DRUG FOR CIRCULATORY ORGAN CONTAINING THE SAME | POLA CHEM IND INC (JP) | 1998-04-29 | — | — | EP | claimed |
| WO-1997018782-A1 | TREATMENT WITH CALCIUM CHANNEL BLOCKERS FOR DRUG-INDUCED HYPERSENSITIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-05-29 | — | — | WO | claimed |
| EP-0675118-A2 | Biphenylderivatives, process for their preparation and their use as medicaments | Eisai Co., Ltd. (JP) | 1995-10-04 | — | — | EP | claimed |
| US-5391552-A | Has strong antagonism against calcium with less side effects | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1995-02-21 | — | — | US | claimed |
| EP-0612738-A1 | Diphenylpiperazine derivative and drug for circulatory organ containing the same | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0555302-A1 | METHOD OF TREATING DEMYELINATING DISEASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-18 | — | — | EP | claimed |
| EP-0549796-A1 | DIPHENYLPIPERAZINE DERIVATIVE AND DRUG FOR CIRCULATORY ORGAN CONTAINING THE SAME | POLA CHEMICAL INDUSTRIES INC (JP) | 1993-07-07 | — | — | EP | claimed |
| WO-1992007564-A2 | METHOD OF TREATING DEMYELINATING DISEASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-14 | — | — | WO | claimed |
| WO-1990006123-A1 | THERAPEUTIC USE OF CALCIUM ENTRY BLOCKERS IN RETINAL OR OPTIC NERVE DYSFUNCTION | HOUSTON BIOTECHNOLOGY INCORPORATED (US) | 1990-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | HAVCR2, HCCS, HELZ | SLC6A2 3163/4885SLC6A4 3507/4885SLC6A3 1892/4885 |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | SLC6A2 3485/4885SLC6A4 3312/4885SLC6A3 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.